Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;306(6):H789-96.
doi: 10.1152/ajpheart.00559.2013. Epub 2014 Jan 24.

Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis

Affiliations

Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis

Tieqiang Zhao et al. Am J Physiol Heart Circ Physiol. 2014 Mar.

Abstract

Vascular endothelial growth factor (VEGF)-C is a key mediator of lymphangiogenesis. Our recent study shows that VEGF-C/VEGF receptors (VEGFR)-3 are significantly increased in the infarcted rat myocardium, where VEGFR-3 is expressed not only in lymph ducts but also in myofibroblasts, indicating that VEGF-C has an unrevealed role in fibrogenesis during cardiac repair. The current study is to explore the regulation and molecular mechanisms of VEGF-C in fibrogenesis. The potential regulation of VEGF-C on myofibroblast differentiation/growth/migration, collagen degradation/synthesis, and transforming growth factor (TGF)-β and ERK pathways was detected in cultured cardiac myofibroblasts. Our results showed that VEGF-C significantly increased myofibroblast proliferation, migration, and type I/III collagen production. Matrix metalloproteinase (MMP)-2 and -9 were significantly elevated in the medium of VEGF-C-treated cells, coincident with increased tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Furthermore, VEGF-C activated the TGF-β1 pathway and ERK phosphorylation, which was significantly suppressed by TGF-β or ERK blockade. This is the first study indicating that in addition to lymphangiogenesis, VEGF-C is also involved in fibrogenesis through stimulation of myofibroblast proliferation, migration, and collagen synthesis, via activation of the TGF-β1 and ERK pathways.

Keywords: ERK; TGF-β1; VEGF-C; collagen degradation; collagen synthesis; myofibroblasts.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Effect of VEGF-C on myofibroblast differentiation, proliferation, and migration. Cultured cardiac fibroblasts automatically differentiated into myofibroblasts at P1 and expressed α-smooth muscle actin (α-SMA; A, left, arrows). Compared with vehicle-treated myofibroblasts, VEGF-C did not affect myofibroblast differentiation (B), significantly increased myofibroblast proliferation (C) and migration (D). A, right: negative control of α-SMA labeling. *P < 0.05 vs. controls (CTL); n = 8/group.
Fig. 2.
Fig. 2.
VEGF-C promotes type I and III collagen synthesis in myofibroblasts. Compared with controls, VEGF-C treatment significantly stimulated type I collagen secretion in a time (A)- and dose-dependent (B) manner. VEGF-C also promoted type III collagen production (C). *P < 0.05 vs. controls (CTL); n = 6/group.
Fig. 3.
Fig. 3.
VEGF-C increases matrix metalloproteinase (MMP)-2 (A) and -9 (B) and tissue inhibitor of metalloproteinase (TIMP)-1 (C) and -2 (D) synthesis in myofibroblasts. MMP-2, MMP-9, TIMP-1 and TIMP-2 were not detectable in the medium of vehicle-treated myofibroblasts. VEGF-C treatment induced MMP-2, MMP-9, TIMP-1, and TIMP-2 release; n = 6/group.
Fig. 4.
Fig. 4.
VEGF-C upregulates TGF-β1 production and Smad2 phosphorylation. Detected by Western blot (A) and ELISA (B), TGF-β1 was not detectable in the medium of vehicle-treated cells, while VEGF-C treatment significantly enhanced TGF-β1 levels in the medium. C: VEGF-C treatment significantly enhanced Smad2 phosphorylation in myofibroblasts. *P < 0.05 vs. controls (CTL); n = 6/group.
Fig. 5.
Fig. 5.
TGF-β blockade abolishes the role of VEGF-C on fibrogenesis. Compared with control cells, TGF-β1 neutralizing antibody significantly suppressed VEGF-C-induced myofibroblast proliferation (B) and type I collagen synthesis (A). TGF-β1 siRNA treatment significantly suppressed VEGF-C-induced type I collagen production (C and D). *P < 0.05 vs. controls; #P < 0.05 vs. VEGFC treatment; n = 6/group.
Fig. 6.
Fig. 6.
VEGF-C stimulates ERK phosphorylation in myofibroblasts. Compared with controls, VEGF-C elevated ERK phosphorylation (p-ERK1/2), which was blocked by the ERK inhibitor U0126 (A). VEGF-C-induced myofibroblast proliferation (B) and type I collagen synthesis (C) were significantly reduced by U0126; n = 6/group. *P < 0.05 vs. controls; #P < 0.05 vs. VEGFC treatment.
Fig. 7.
Fig. 7.
Effect of the ERK inhibitor on VEGF-C-induced TGF-β1 production in myofibroblasts. VEGF-C enhanced TGF-β1 production by myofibroblasts, which was not diminished by U0126; n = 6/group.

References

    1. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184–195, 2007 - PMC - PubMed
    1. Chaudary N, Milosevic M, Hill RP. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer. Gynecol Oncol 123: 393–400, 2011 - PubMed
    1. Chen W, Frangogiannis NG. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta 1833: 945–953, 2013 - PMC - PubMed
    1. Cohen S, Efraim AN, Levi-Schaffer F, Eliashar R. The effect of hypoxia and cycloxygenase inhibitors on nasal polyp derived fibroblasts. Am J Otolaryngol 32: 564–573, 2011 - PubMed
    1. Daskalopoulos EP, Hermans KC, Blankesteijn WM. Cardiac (myo)fibroblast: novel strategies for its targeting following myocardial infarction. Curr Pharm Des 2013. June 18 [Epub ahead of print] - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources